ANE syndrome

ANE syndrome, also known as Alopecia-Nail dystrophy-Endocrine abnormalities syndrome, is an extremely rare genetic disorder characterized by the triad of alopecia (hair loss), nail dystrophy (abnormal nail development), and endocrine disturbances, particularly hypopituitarism. The ICD-10 classification under E23.0 reflects the hypopituitarism component, which can manifest as growth hormone deficiency, hypogonadism, and other pituitary hormone deficiencies. The condition affects multiple body systems including the integumentary system (skin, hair, and nails) and the endocrine system. Patients typically present with sparse or absent scalp hair, eyebrows, and eyelashes, along with dystrophic or absent nails. The endocrine manifestations can include short stature due to growth hormone deficiency, delayed or absent puberty, and other hormonal imbalances related to pituitary dysfunction. The severity and combination of features can vary among affected individuals. Treatment is primarily supportive and symptomatic. Hormone replacement therapy is used to address specific endocrine deficiencies, including growth hormone supplementation for growth failure and sex hormone replacement for hypogonadism. Dermatological management may include wigs and cosmetic approaches for alopecia. Regular endocrine monitoring is essential to identify and treat hormonal deficiencies as they develop. There is currently no curative therapy for this condition.

Common questions about ANE syndrome